---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-068277"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2023-12-05T23:59:59+00:00"
generated_at: "2026-06-07T18:07:26.956252+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Olema reports positive Phase 1b/2 combo data for palazestrant; Phase 3 OPERA-01 enrolling

## Summary
- Palazestrant + ribociclib (19 patients) well-tolerated; no dose-limiting toxicities, no drug-drug interaction.
- Palazestrant + palbociclib (46 patients): clinical benefit rate 46% overall, 60% in ESR1 mutant, 71% in CDK4/6-naïve.
- OPERA-01 Phase 3 monotherapy trial initiated; first patient dosed November 2023; sites activated.
- Company anticipates potential Phase 3 combo trial start with ribociclib as early as end 2024.

## SEC filing metadata
- accession: 0000950170-23-068277
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2023-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017023068277/0000950170-23-068277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017023068277/olma-20231205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-068277
- JSON: https://secwatch.observer/filing/0000950170-23-068277.json
- Plain text: https://secwatch.observer/filing/0000950170-23-068277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.